You are here

Diabetes Drug Market Expected to Double Over Next Decade

Experts think SGLT-2 inhibitors will take the spotlight (Oct. 15)

Decision Resources, a research firm located in Burlington, Mass., has predicted that the type 2 diabetes drug market will nearly double over the next decade, increasing from $26 billion in 2011 to almost $50 billion in 2021 in the U.S., the U.K., France, Germany, Italy, Spain, and Japan. The main factors fueling this growth will be a growing drug-treated patient population and a large pipeline of products expected to launch during this period.

The company reports that the dipeptidyl peptidase IV (DPP-IV) inhibitor drug class will continue to expand, given the increasing use of these agents in the second-line setting. Sitagliptin (Januvia/Xelevia, Merck) will remain the leading agent in the class. The glucagon-like peptide-1 (GLP-1) receptor agonist class will also grow, with major-market sales predicted to reach nearly $8 billion by 2021. These agents are expensive and require injections, but they have a positive efficacy profile and can elicit weight loss, the company said.

In addition, sodium glucose transporter-2 (SGLT-2) inhibitors — notably dapagliflozin (AstraZeneca/Bristol-Myers Squibb) and canagliflozin (Johnson & Johnson) — are expected to influence the treatment paradigm for type 2 diabetes. It is anticipated that dapagliflozin will launch in Europe in late 2012.

Interviewed thought leaders considered the SGLT-2 inhibitors to be the most interesting agents that will emerge during the forecast period, based on their weight-loss efficacy, versatility, and low risk of hypoglycemia.

The survey findings also indicated that use of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist class will continue to decline through 2021, given the safety issues surrounding both rosiglitazone (Avandia, GlaxoSmithKline) and pioglitazone (Actos, Takeda), as well as the generic erosion of pioglitazone.

Source: Decision Resources, October 15, 2012.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress